After the trial: What next? Getting a drug into clinic

Listen to Professor Richard Keen, from the Royal National Orthopaedic Hospital, London, explain the journey a drug takes from a successful clinical trial to a patient’s bedside. Speaking from a rare disease perspective, Professor Keen breaks down the vital roles of the MHRA and NICE in the UK regulatory process. The conversation focuses specifically on the challenges and realities facing those living with the ultra-rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP). To learn more and listen to the full discussion, visit: fopfriends.com/research/